Last checked at 24 Aug 2021 11:07
24 August 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
Director & PDMR Share Purchases
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that each member of the Board of Directors and PDMR, Ewa Flynn (Chief Financial Officer) have on 23 & 24 August 2021 purchased in total 670,000 ordinary shares of 10p in the Company ("Ordinary Shares").
Details of the share purchases by the Board and their current interests in shares following the transactions are set out below.
NAME & TITLE | ORDINARY SHARES PURCHASED & PURCHASE PRICE | NUMBER OF ORDINARY SHARES HELD POST TRANSACTION | % OF ISSUED SHARE CAPITAL |
Tim McCarthy Chairman & Chief Executive Officer | 250,000 @ 8.26p | 288,462 | 0.12% |
Dr Tim Franklin Chief Operating Officer | 125,000 @ 7.99p | 125,000 | 0.05% |
Dr Sanjeev Pandya Senior Non-Executive Director | 125,000 @ 8.00p | 125,000
| 0.05% |
Lisa Baderoon Non-Executive Director & Head of Investor Relations | 140,000 @ 8.1957p | 183,963 | 0.07% |
Ewa Flynn Chief Financial Officer & Company Secretary | 30,000 @ 7.892p | 30,000 | 0.01% |
Full disclosure of the transactions by persons discharging managerial responsibilities and persons closely associated with them ("PDMR's") are detailed at the end of the announcement.
End
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. on publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||
a) | Name | Tim McCarthy | |
2 | Reason for the notification | ||
a) | Position/status | Chairman and Chief Executive Officer | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | ImmuPharma PLC | |
b) | LEI | 213800VZKGHXC7VUS895 | |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 10p each
ISIN: GB0033711010 | |
b) | Nature of the transaction | On-market purchase | |
c)
| Price(s) and volume(s)
| Price | Volume |
8.26p | 250,000 | ||
d)
| Aggregated information
- Aggregated volume
- Price
|
| |
e) | Date of the transaction | 23 August 2021 | |
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||
a) | Name | Dr Tim Franklin | |
2 | Reason for the notification | ||
a) | Position/status | Chief Operating Officer | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | ImmuPharma PLC | |
b) | LEI | 213800VZKGHXC7VUS895 | |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 10p each
ISIN: GB0033711010 | |
b) | Nature of the transaction | On-market purchase | |
c)
| Price(s) and volume(s)
| Price | Volume |
7.99p | 125,000 | ||
d)
| Aggregated information
- Aggregated volume
- Price
|
| |
e) | Date of the transaction | 24 August 2021 | |
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||
a) | Name | Dr Sanjeev Pandya | |
2 | Reason for the notification | ||
a) | Position/status | Senior Non-Executive Director | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | ImmuPharma PLC | |
b) | LEI | 213800VZKGHXC7VUS895 | |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 10p each
ISIN: GB0033711010 | |
b) | Nature of the transaction | On-market purchase | |
c)
| Price(s) and volume(s)
| Price | Volume |
8p | 125,000 | ||
d)
| Aggregated information
- Aggregated volume
- Price
|
| |
e) | Date of the transaction | 23 August 2021 | |
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||
a) | Name | Lisa Baderoon | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Director & Head of Investor Relations | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | ImmuPharma PLC | |
b) | LEI | 213800VZKGHXC7VUS895 | |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 10p each
ISIN: GB0033711010 | |
b) | Nature of the transaction | On-market purchase | |
c)
| Price(s) and volume(s)
| Price | Volume |
8.1957p | 140,000 | ||
d)
| Aggregated information
- Aggregated volume
- Price
|
| |
e) | Date of the transaction | 23 August 2021 | |
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||
a) | Name | Ewa Flynn | |
2 | Reason for the notification | ||
a) | Position/status | Chief Financial Officer (PDMR) | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | ImmuPharma PLC | |
b) | LEI | 213800VZKGHXC7VUS895 | |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 10p each
ISIN: GB0033711010 | |
b) | Nature of the transaction | On-market purchase | |
c)
| Price(s) and volume(s)
| Price | Volume |
7.892p | 30,000 | ||
d)
| Aggregated information
- Aggregated volume
- Price
|
| |
e) | Date of the transaction | 23 August 2021 | |
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | |